Treatment with LNA–anti–miR-155 decreases the severity of aGVHD and prolongs the survival of MHC-mismatched recipient mice. (A) Schematic presentation of the schedule of oligonucleotide injections after transplantation. Briefly, lethally irradiated recipient F1 mice transplanted with BM (5 × 10⁶) plus B6 WT spleen cells (20 × 10⁶) were treated with LNA–anti–miR-155 (n = 10) or control LNA oligos (n = 10) starting at day 7 with a loading dose 25 mg/kg followed by 5 mg/kg intravenously twice weekly up to day 30 after infusion of donor B6 splenocytes. (A) Clinical GVHD scores after transplantation from lethally irradiated F1 recipients transplanted with B6 donor BM and splenocytes and treated with LNA–anti–miR-155 or control oligonucleotide. P values were obtained by using t test. (B) Survival rate of the different recipient F1 mice groups. Comparisons between survival curves were performed using log-rank test. (D) miR-155 expression in spleen from LNA–anti–miR-155 or control treated mice as measured by RT-PCR. Data represent the average of 3 mice. Experiments performed in triplicate. Bars represent SE.